Myomics: AI-Powered Cardiac MRI Analysis by Phantomics

Myomics is the flagship cardiac MRI analysis platform developed by Phantomics, Inc., a medical AI company headquartered in Seoul, South Korea. Built on deep learning, Myomics automates the traditionally labor-intensive process of cardiac MRI post-processing — transforming what once took a radiologist or cardiologist 30–60 minutes of manual contouring and calculation into a workflow that completes in minutes, with a single click from image to finished report.

What Myomics Does

Cardiac MRI is widely regarded as the gold-standard imaging modality for assessing heart structure, function, and tissue characteristics, but its clinical adoption has historically been limited by the time and expertise required for manual analysis. Myomics addresses this bottleneck through fully automated deep learning–based segmentation and quantification across the core sequences used in cardiac MRI protocols:

• Cardiac Function Analysis — automated segmentation of the left and right ventricles from CINE MRI sequences to calculate ejection fraction, end-diastolic and end-systolic volumes, stroke volume, and myocardial mass, with additional dynamic metrics such as peak ejection rate (PER) and peak filling rate (PFR).
• T1 Mapping and ECV Quantification — automated myocardial T1 value measurement and extracellular volume (ECV) fraction calculation, a key biomarker for detecting diffuse myocardial fibrosis, amyloidosis, and other infiltrative or inflammatory conditions — without requiring manual region-of-interest drawing.
• T2 Mapping — automated quantification for the detection of myocardial edema, supporting diagnosis of acute myocarditis and other inflammatory cardiac conditions.
• T2* Mapping — quantification of myocardial and hepatic iron overload, relevant for conditions such as thalassemia and hemochromatosis.
• One-click reporting — Myomics condenses the full analysis pipeline, from raw DICOM images to a structured, exportable clinical report, into a single streamlined workflow, minimizing manual steps and inter-observer variability.

Regulatory Status and Clinical Validation

Myomics has received regulatory clearance in multiple major markets, including the U.S. FDA (510(k)), Japan's PMDA, and approvals in South Korea, Taiwan, Thailand, and Malaysia. (Some advanced features remain research-use-only in certain jurisdictions pending further clearance.)

The platform's accuracy and clinical utility have been validated in peer-reviewed literature, including studies published in journals such as Quantitative Imaging in Medicine and Surgery, which assessed Myomics' automated T2 mapping analysis against manual reference standards in the diagnostic workup of myocarditis. Myomics is currently deployed in more than 20 hospitals across Korea and a growing number of international clinical sites, including collaborations with hospitals in Malaysia.

Recognition and Partnerships

Myomics has received industry recognition including the CES 2024 Innovation Award and the KHF (Korea Healthcare Congress) 2025 Innovation Award. Phantomics has also pursued strategic collaborations with major imaging OEMs and distribution partners — including a joint research collaboration with Siemens Healthineers on AI-based cardiac MRI and CT analysis, and a partnership with medical device distributor Yujeong Meditech to launch a premium, non-contrast cardiac MRI screening package. This solution pairs Myomics with a specialized MRI protocol that completes a full cardiac scan in under 10 minutes without the need for contrast agents, with AI analysis completed in under 5 minutes — enabling same-day detection of conditions such as myocarditis, heart failure, and myocardial infarction in a health-screening setting.

Why It Matters

By automating what has historically been a slow, subjective, and expertise-dependent process, Myomics aims to expand access to advanced cardiac diagnostics — making comprehensive, quantitative cardiac MRI analysis practical not only in academic tertiary centers but also in community hospitals and health-screening programs where dedicated cardiac imaging specialists may not be available. This combination of automation, speed, and validated accuracy positions Myomics as a core tool in Phantomics' broader mission of making precision cardiovascular imaging more accessible, consistent, and scalable.